Group discussion on selected HIV/AIDS costing and cost-effectiveness articles. Michelle Remme ([email protected]) HIV Modelling and Economics, Social and Mathematical Epidemiology Group London School of Hygiene and Tropical Medicine. Improving health worldwide. www.lshtm.ac.uk.
comparable and quality data is limited
Pick one figure/table that summarises these best
Fig. 2. Change in median per-patient financial costs in successive 6-month periods, from start of HIV treatment scale-up in eachsite through 2006–2007 (2009 US$).
(Menzies et al., 2011, AIDS)